RCTs finally look beyond RECIST: Treatment beyond first RECIST-defined progression
29 January 2020
- Post-hoc analysis on an atezolizumab RCT study used treatment beyond first RECIST
- This endpoint means that RCTs are moving towards being more aligned with real-world evidence studies, which often use TTD
Click here and here to read the source articles
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at email@example.com